Imdelltra (tarlatamab-dlle) — Medica
small cell lung cancer
Initial criteria
- age ≥ 18 years
- patient has primary progressive, relapsed, or refractory extensive stage disease
- patient has previously received platinum-based chemotherapy
- prescribed by or in consultation with an oncologist
Approval duration
1 year